Literature DB >> 18814277

Cancer-retina antigens as potential paraneoplastic antigens in melanoma-associated retinopathy.

Alexandr V Bazhin1, Claudia Dalke, Nadine Willner, Oliver Abschütz, Hannes G H Wildberger, Pavel P Philippov, Reinhard Dummer, Jochen Graw, Martin Hrabé de Angelis, Dirk Schadendorf, Viktor Umansky, Stefan B Eichmüller.   

Abstract

Melanoma-associated retinopathy is a rare paraneoplastic neurological syndrome characterized by retinopathy in melanoma patients. The main photoreceptor proteins have been found to be expressed as cancer-retina antigens in melanoma. Here we present evidence that these can function as paraneoplastic antigens in melanoma-associated retinopathy. Sera and one tumor cell line of such patients were studied and ret-transgenic mice spontaneously developing melanoma were used as a murine model for melanoma-associated retinopathy. Splenocytes and sera were used for adoptive transfer from tumor-bearing or control mice to wild-type mice. Retinopathy was investigated in mice by funduscopy, electroretinography and eye histology. Expression of photoreceptor proteins and autoantibodies against arrestin and transducin were detected in melanoma-associated retinopathy patients. In tumor-bearing ret-transgenic mice, retinopathy was frequently (13/15) detected by electroretinogram and eye histology. These pathological changes were manifested in degenerations of photoreceptors, bipolar cells and pigment epithelium as well as retinal detachment. Mostly these defects were combined. Cancer-retina antigens were expressed in tumors of these mice, and autoantibodies against arrestin were revealed in some of their sera. Adoptive transfer of splenocytes and sera from tumor-bearing into wild-type mice led to the induction of retinopathy in 4/16 animals. We suggest that melanoma-associated retinopathy can be mediated by humoral and/or cellular immune responses against a number of cancer-retina antigens which may function as paraneoplastic antigens in melanoma-associated retinopathy.

Entities:  

Mesh:

Year:  2009        PMID: 18814277     DOI: 10.1002/ijc.23909

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  12 in total

1.  Update on paraneoplastic neurologic disorders.

Authors:  Myrna R Rosenfeld; Josep Dalmau
Journal:  Oncologist       Date:  2010-05-17

2.  [Arch-shaped retinal appearance of a previously healthy women].

Authors:  M Khattab; N Feltgen; S Bemme; H Hoerauf; M Storch
Journal:  Ophthalmologe       Date:  2017-07       Impact factor: 1.059

3.  Delayed presentation of melanoma-associated retinopathy and subsequent resolution with cytoreduction surgery.

Authors:  Richard E Stead; Maryke A Fox; Emily Staples; Chea S Lim
Journal:  Doc Ophthalmol       Date:  2013-06-22       Impact factor: 2.379

4.  Autoantibodies to transient receptor potential cation channel, subfamily M, member 1 in a Japanese patient with melanoma-associated retinopathy.

Authors:  Yukiko Morita; Kazuhiro Kimura; Youichiro Fujitsu; Atsushi Enomoto; Shinji Ueno; Mineo Kondo; Koh-Hei Sonoda
Journal:  Jpn J Ophthalmol       Date:  2014-01-29       Impact factor: 2.447

5.  cGMP-phosphodiesterase 6, transducin and Wnt5a/Frizzled-2-signaling control cGMP and Ca(2+) homeostasis in melanoma cells.

Authors:  Alexandr V Bazhin; Vojtech Tambor; Boyan Dikov; Pavel P Philippov; Dirk Schadendorf; Stefan B Eichmüller
Journal:  Cell Mol Life Sci       Date:  2009-11-28       Impact factor: 9.261

6.  Autoantibodies against the Ca(2+)-binding protein recoverin in blood sera of patients with various oncological diseases.

Authors:  Marina S Savchenko; Maria A Goncharskaia; Elena E Skorikova; Stefan B Eichmüller; Nikolay E Kushlinsky; Alexandr V Bazhin; Pavel P Philippov
Journal:  Oncol Lett       Date:  2011-10-31       Impact factor: 2.967

7.  The cancer-retina antigen recoverin as a potential biomarker for renal tumors.

Authors:  Marina O Golovastova; Larisa V Tsoy; Anna V Bocharnikova; Dmitry O Korolev; Olga S Gancharova; Ekaterina A Alekseeva; Ekaterina B Kuznetsova; Lyudmila V Savvateeva; Elena E Skorikova; Vladimir V Strelnikov; Vladimir A Varshavsky; Andrey Z Vinarov; Vladimir N Nikolenko; Peter V Glybochko; Evgeni Yu Zernii; Andrey A Zamyatnin; Alexandr V Bazhin; Pavel P Philippov
Journal:  Tumour Biol       Date:  2016-01-26

Review 8.  Autoantibody targets and their cancer relationship in the pathogenicity of paraneoplastic retinopathy.

Authors:  Grazyna Adamus
Journal:  Autoimmun Rev       Date:  2009-01-23       Impact factor: 9.754

9.  Serum Autoantibody Profiling of Patients with Paraneoplastic and Non-Paraneoplastic Autoimmune Retinopathy.

Authors:  Josianne C Ten Berge; Joost van Rosmalen; Jacolien Vermeer; Cecilia Hellström; Cecilia Lindskog; Peter Nilsson; Ulrika Qundos; Aniki Rothova; Marco W J Schreurs
Journal:  PLoS One       Date:  2016-12-08       Impact factor: 3.240

10.  Serum TRPM1 autoantibodies from melanoma associated retinopathy patients enter retinal on-bipolar cells and attenuate the electroretinogram in mice.

Authors:  Wei-Hong Xiong; Robert M Duvoisin; Grazyna Adamus; Brett G Jeffrey; Celia Gellman; Catherine W Morgans
Journal:  PLoS One       Date:  2013-08-01       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.